Although some questions still remain around complement inhibitors, including choice of agent and length of treatment, C3G and primary IC-MPGN patients can certainly look forward to a brighter future with meaningful differences to their lives. Here, RAPGEF1 is linked to primary membranoproliferative glomerulonephritis.